Мировой рынок агонистов гуанилатциклазы-С – тенденции отрасли и прогноз до 2030 года

Анализ и размер рынка агонистов гуанилатциклазы-С

В последние годы ожидается, что рынок агонистов гуанилатциклазы-С будет быстро расти в течение прогнозируемого периода. Согласно исследованию ООН World Population Ageing Highlight 2020, прогнозируется, что численность гериатрического населения во всем мире увеличится с 727 миллионов в 2020 году до 1,5 миллиарда к 2050 году, что представляет собой почти двукратное увеличение, в то время как доля гериатрического населения в 2020 году составляла около 9,3% и, как ожидается, вырастет до 16% к 2050 году. Гериатрическое население подвержено высокому риску желудочно-кишечных расстройств. Это приводит к высокому спросу на агонисты гуанилатциклазы-С в секторе здравоохранения.

Data Bridge Market Research анализирует, что рынок агонистов гуанилатциклазы-С, который в 2022 году составил 576,03 млн долларов США, к 2030 году, вероятно, достигнет 884,03 млн долларов США и, как ожидается, будет претерпевать среднегодовой темп роста в 5,5% в течение прогнозируемого периода. «Trulance» доминирует в сегменте лекарственных средств на рынке агонистов гуанилатциклазы-С из-за растущего спроса на более совершенные методы лечения пациентов. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, курируемые Data Bridge Market Research, также включают глубокий экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Область отчета и сегментация рынка

Market Definition

Constipation associated with irritable bowel syndrome (IBS) and chronic cons1tipation of unclear cause (idiopathic constipation) in adults are treated with guanylate cyclase-C agonists. IBS is characterized by stomach pain or cramps, bloating, and infrequent or difficult bowel movements. Guanylate cyclase-C agonists are prescription pharmaceuticals that can be taken alone or in combination with other drugs.

Global  Guanylate Cyclase-C Agonists Market Dynamics

Drivers

• Increasing incidences of gastrointestinal disorders

The rising incidences of gastrointestinal disorders such as chronic idiopathic constipation and irritable bowel syndrome is anticipated to influence the guanylate cyclase-C agonists market's growth. Growing smoking addiction and surging alcohol consumption are some of the causes of gastrointestinal disorders.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of guanylate cyclase-C agonists market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the guanylate cyclase-C agonists market. In addition, high disposable income and sedentary lifestyle of people will result in the expansion of guanylate cyclase-C agonists market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the guanylate cyclase-C agonists market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

• Increasing adoption of targeted therapies

GC-C agonists offer a targeted approach to treating gastrointestinal disorders by specifically activating the GC-C receptor in the intestinal epithelium. This targeted mechanism of action can provide advantages such as improved efficacy and reduced side effects compared to traditional therapies. As the trend towards personalized medicine and targeted therapies continues to grow, GC-C agonists may find increased adoption in the market.

Restraints/Challenges

• Stringent regulatory requirements

Developing and gaining regulatory approval for new pharmaceutical products, including GC-C agonists, can be a complex and time-consuming process. Meeting the stringent regulatory requirements set by health authorities, such as the FDA and EMA, can pose challenges and delays in launching these therapies in the market.

• Limited awareness among healthcare professionals

Despite the potential benefits of GC-C agonists, there may be a lack of awareness and understanding among healthcare professionals about their mechanism of action, efficacy, and appropriate patient selection. This can hinder their adoption and restrict market growth.

This guanylate cyclase-C agonists market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the guanylate cyclase-C agonists market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In May 2020, Synthetic Biologics announced the initiation of a Phase 2b clinical trial evaluating SYN-004 (a GC-C agonist) for the prevention of Clostridium difficile infection (CDI) in patients hospitalized for a lower respiratory tract infection
• In June 2020, AbbVie announced that it had completed the divestiture of the rights to linaclotide (a GC-C agonist) and the related assets to Nestlé Health Science
• In March 2020, Shionogi announced that the European Medicines Agency (EMA) had accepted its Marketing Authorization Application (MAA) for naldemedine (a PAMORA with GC-C agonist activity) for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain
• In February 2020, Ardelyx announced positive results from the Phase 3 AMPLIFY study evaluating tenapanor (a GC-C agonist) for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis

Global Guanylate Cyclase-C Agonists Market Scope

The Guanylate Cyclase-C Agonists market is segmented on the basis of drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug

• Trulance
• Linzess

Application

• Irritable Bowel Syndrome
• Chronic Idiopathic Constipation
• Others

Dosage

• Injection
• Tablet
• Others

Route of Administration

• Intravenous
• Oral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Guanylate Cyclase-C Agonists Market Regional Analysis/Insights

The guanylate cyclase-C agonists market is analysed and market size insights and trends are provided by country, drug, application, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the guanylate cyclase-C agonists market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, rest of Middle East & Africa.

North America is expected to dominate the guanylate cyclase-C agonists market because of the well-established healthcare sector in this region. In addition, growing presence of major key players will further propel the market’s growth rate in this region. 

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Рынок агонистов гуанилатциклазы-С также предоставляет вам подробный анализ рынка с точки зрения роста расходов здравоохранения на капитальное оборудование в каждой стране, установленной базы различных видов продукции для рынка агонистов гуанилатциклазы-С, влияния технологий с использованием кривых жизненно важного цикла и изменений в сценариях регулирования здравоохранения и их влияния на рынок агонистов гуанилатциклазы-С.

Конкурентная среда и анализ доли рынка агонистов гуанилатциклазы-С

Конкурентная среда рынка агонистов гуанилатциклазы-С содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта, доминировании в применении. Приведенные выше данные касаются только фокуса компаний на рынке агонистов гуанилатциклазы-С.

Некоторые из основных игроков, работающих на рынке агонистов гуанилатциклазы-С:

• Эбботт (США)
• F. Hoffmann-La Roche Ltd. (Швейцария)
• Mylan NV (США)
• Teva Pharmaceutical Industries Ltd. (Израиль)
• Санофи (Франция)
• Новартис АГ (Швейцария)
• Sun Pharmaceutical Industries Ltd. (Индия)
• Takeda Pharmaceutical Company Limited (Япония)
• Pfizer Inc. (США)
• GlaxoSmithKline plc (Великобритания)
• АстраЗенека (Великобритания)
• Johnson & Johnson Private Limited (США)
• Boehringer Ingelheim International GmbH. (Германия)
• Астеллас Фарма Инк. (Япония)
• Аллерган (Ирландия)
• Корпорация Mitsubishi Tanabe Pharma (Япония)
• Kyowa Kirin Co., Ltd. (Япония)
• Liminal BioSciences Inc. (Канада)
• Avexegen Therapeutics, Inc. (США)
• AbbVie Inc. (США)

SKU-68162